Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | USP8 | P40818 | 1/20 | 0.30 |
| ▸ | USP7 | Q93009 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297778 | 0.81 | KDM4E (0.46) | KDM4EALDH1A1POLBCYP11B2GRM5 | |
| SCHEMBL20113370 | 0.80 | USP8 (0.35) | KDM4EALDH1A1POLBCYP11B2DAO | |
| SCHEMBL18283690 | 0.80 | POLB (0.48) | KDM4EALDH1A1POLBDAOPLAU | |
| SCHEMBL29368821 | 0.80 | USP8 (0.35) | KDM4EALDH1A1POLBCYP11B2DAO | |
| SCHEMBL18283565 | 0.80 | POLB (0.48) | KDM4EALDH1A1POLBDAOPLAU | |
| SCHEMBL31410007 | 0.73 | DAO (0.37) | ALDH1A1DAOPLAU | |
| SCHEMBL31409944 | 0.72 | — | — | |
| SCHEMBL29877981 | 0.71 | KDM4E (0.32) | KDM4EALDH1A1POLB | |
| SCHEMBL22976756 | 0.70 | KDM4E (0.40) | KDM4EALDH1A1POLBCYP11B2GRM5 | |
| SCHEMBL2220883 | 0.69 | PLAU (0.39) | ALDH1A1DAOPLAUUSP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | KDM4E 4514/4885ALDH1A1 4555/4885POLB 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.